Current Report Filing (8-k)
January 09 2017 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 9, 2017
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36167
|
|
26-3931704
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
85 Wells Avenue, 2nd Floor
Newton, MA
|
|
02459
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
A copy of the slide presentation that will be used by representatives
of Karyopharm Therapeutics Inc. (the Company) in connection with investor meetings and presentations from time to time (the Corporate Presentation) is attached to this Current Report on Form
8-K
as Exhibit 99.1. The Corporate Presentation is current as of January 9, 2017, and the Company disclaims any obligation to correct or update this material in the future.
The information in this Form
8-K
(including Exhibit 99.1) shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not
filed:
99.1 Corporate Presentation current as of January 9, 2017
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
KARYOPHARM THERAPEUTICS INC.
|
|
|
|
Date: January 9, 2017
|
|
By:
|
|
/s/ Christopher B. Primiano
|
|
|
|
|
Christopher B. Primiano
|
|
|
|
|
Senior Vice President, Operations, Business Development, General Counsel and Secretary
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Corporate Presentation current as of January 9, 2017
|
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024